Clinical Study Synopsis
|
|
- Norma White
- 5 years ago
- Views:
Transcription
1 Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare Professionals should always refer to the specific labelling information approved for the patient's country or region. Data in this document or on the related website should not be considered as prescribing advice. The study listed may include approved and non-approved formulations or treatment regimens. Data may differ from published or presented data and are a reflection of the limited information provided here. The results from a single trial need to be considered in the context of the totality of the available clinical research results for a drug. The results from a single study may not reflect the overall results for a drug. The following information is the property of Bayer HealthCare AG. Reproduction of all or part of this report is strictly prohibited without prior written permission from Bayer HealthCare AG. Commercial use of the information is only possible with the written permission of the proprietor and is subject to a license fee. Please note that the General Conditions of Use and the Privacy Statement of bayerhealthcare.com apply to the contents of this file.
2 Webposting Clinical Trial Results Synopsis Study Sponsor: Bayer HealthCare AG Study Number: NCT Study Phase: IIIB Study Title: A prospective, randomized, double dummy, double blind, multi-center multinational trial comparing the efficacy and safety of moxifloxacin 400 mg PO QD 24 hours for 14 days to that of levofloxacin 500 mg PO QD 24 hours plus metronidazole 500 mg BID for 14 days in subjects with an uncomplicated pelvic inflammatory disease. Moxifloxacin, Metronidazole, and Levofloxacin in Asia (MONALISA Study) Therapeutic Area: Anti-Infective Name of Test Product: BAY / moxifloxacin HCl / Avelox Active Ingredient: Moxifloxacin, oral 400mg tablets Dosage: Moxifloxacin was administered orally 400 mg once daily (od) for 14 days. Ceftriaxone 250 mg was administered intramuscularly once at the During Therapy visit in subjects with a documented gonococcal infection. Reference Therapy: Oral levofloxacin 500 mg once daily (od) combined with oral metronidazole 500 mg twice daily (bid) Dosage: Levofloxacin 500 mg was administered as 2 x 250 mg tablets once daily (od) and metronidazole 500 mg was administered as one tablet twice daily (bid) for 14 days. Ceftriaxone 250 mg was administered intramuscularly once at the During Therapy visit in subjects with a documented gonococcal infection. Placebo: Not applicable Route of Administration: Oral ( moxifloxacin, levofloxacin and metronidazole); intramuscularly (ceftriaxone) Treatment Duration: The planned duration of the study was 6 to 8 weeks, including a 14 day treatment period and a 4- to 6-week (untreated) follow up period. Study Period: Date of first subjects first visit: 09 January 2007 Date of last subjects last visit 12 May 2008 Methodology: This was a multinational, multi-center, prospective, randomized, double-blind, phase IIIb study conducted using a parallel group design. Subjects matching eligibility criteria were assigned randomly to receive 14 days of treatment with either oral moxifloxacin 400 mg once daily or oral levofloxacin 500 mg once daily plus oral metronidazole 500 mg bid. One visit was planned during the treatment period (Day 4 to 7) to assess clinical progress. A single intramuscular injection of ceftriaxone 250 mg was administered at the During Therapy visit in all subjects with a documented gonococcal infection. Subjects were then followed until Day 28 to 42 after therapy with study medication was completed. Clinical, bacteriological, and laboratory examinations were performed pretreatment and at the test of cure (TOC) visit (7 to 14 days after last administration of study medication). In addition, all successfully treated subjects and subjects evaluated as indeterminate at TOC who did not receive additional antibiotic therapy had a follow-up evaluation 28 to 42 days after completion of study medication. Study Site: The study was conducted at 13 centers in 7 countries, including 6 centers in mainland China, 1 center in Indonesia, 1 center in South Korea, 1 center in the Philippines, 1 center in Pakistan, 1 center in Thailand, and 2 centers in Taiwan. Altogether, 463 subjects were enrolled.
3 Main Inclusion Criteria: Females aged 18 years or above Diagnosis of pelvic inflammatory disease (PID) based on all of the following symptoms Pelvic discomfort Direct lower abdominal tenderness with or without rebound tenderness Adnexal tenderness on bimanual vaginal examination Cervical motion tenderness on bimanual vaginal examination And one or more of the following signs: Rectal/tympanic/oral temperature value > 38.0 C or axillary temperature value > 37.5 C Elevated C-reactive protein (CRP) value (above the upper limit of normal [ULN] for the respective laboratory) White blood cell count (WBC) 10,500/mm3 Laparoscopic evidence of PID Signs suggestive of cervical infection, including mucopurulent cervical discharge or positive Gram stain for Gram-negative intracellular diplococci from the endocervix Untreated, recent (less than 14 days) documented gonococcal or chlamydial cervicitis Endocervical cultures and polymerase chain reaction (PCR) tests performed within 48 hours prior to start of therapy Willing to use condoms as barrier contraception until the completion of the TOC (or alternative antibiotic) visit Willing to have a physical examination at the different assessment visits Subjects who signed an informed consent form prior to study entry Study Objectives: Evaluation Criteria: Overall: The objectives of this study were to compare the efficacy and safety of oral moxifloxacin 400 mg administered once daily with those of oral levofloxacin 500 mg once daily plus oral metronidazole 500 mg twice daily in adult subjects with an uncomplicated PID. Efficacy (Primary): The primary efficacy variable was clinical response 7 to 14 days after the completion of study drug therapy (TOC visit). Efficacy (Secondary): Secondary efficacy parameters included the following: Clinical response on Treatment Day 4 to 7. Bacteriological response at the TOC visit. Clinical response at the TOC visit in subjects with a bacteriologically documented infection. Clinical and bacteriological responses at the Follow-up visit (28 to 42 days after the end of therapy). Necessity for modifying the antibiotic therapy for PID up to the TOC visit or for instituting an antibiotic therapy (for PID recurrence) from TOC up to the end of follow-up. Safety Evaluation of safety was based on adverse events, physical examinations including vital signs determination, and clinical laboratory tests
4 Statistical Methods: Efficacy (Primary): All statistical tests were 2-sided and performed at the 0.05 significance level. The primary efficacy variable was clinical response at the TOC visit, where failures from the During Therapy visit (Day 4 to 7) were carried forward (ie, successes were defined as subjects with clinical cure at TOC; failures were subjects with failure at the During Therapy visit or improvement or failure at TOC). For success rates, a 95% confidence interval (CI) of the difference between the two clinical success rates (moxifloxacin minus comparator group) was calculated using Mantel-Haenszel weights based on centers. If the lower limit of this 95% CI was greater than 15%, it was proven that treatment with moxifloxacin is clinically not less effective than the comparator treatment regimen. If the lower limit of this 95% CI was greater than 0, superiority of treatment with moxifloxacin was proven. Efficacy (Secondary): As secondary efficacy analyses, clinical response during treatment (4 to 7 days after start of treatment) and at the Follow-up visit (28 to 42 days post-therapy), and clinical response at the TOC visit in subjects with bacteriologically documented infection, were analyzed exploratively in the same way as the primary efficacy variable. In addition, bacteriological responses at the TOC and Follow-up visits were analyzed exploratively in the same way as the primary efficacy variable based on the subgroup of microbiologically valid subjects. At the TOC visit, persistence, presumed persistence, and superinfection were considered bacteriological failures. At the Follow-up visit, recurrence and reinfection were treated as bacteriological failures. A bacteriological success was defined as a subject with a bacteriological response classified as eradication or presumed eradication without occurrence of a superinfection. The correlation between clinical and bacteriological response was to be explored. Safety All analyses of safety endpoints were to be descriptive only; no formal testing was to be performed. All safety tabulations were to be produced for the ITT population (which is equivalent to the valid for safety population). Number of Subjects: A total of 460 randomized subjects (230 subjects/treatment arm) were planned (Revised per Amendment 2, dated 21 Dec 2007), with at least 200 subjects from mainland China. A total of 463 subjects were actually enrolled; 228 subjects were randomized into the moxifloxacin group and 232 into the levofloxacin/metronidazole group. Three subjects from mainland China were not randomized. Results Summary Subject Disposition and Baseline Figure 1 Subject Enrollment and Disposition 463 enrolled 460 randomized 412 completed treatment 399 completed study* Moxifloxacin 400 mg OD Levofloxacin 500 mg OD plus Metronidazole 500 mg BID 228 randomized 203 completed treatment 201 completed study* 232 randomized 209 completed treatment 198 completed study* 1 Subjects who had Follow-up assessment or alternative antibiotic assessment visit. Abbreviations: BID = twice daily; OD = once daily Source: Tables /1.1 and /2.1
5 Results Summary Efficacy The study demonstrated that a 14-day treatment with moxifloxacin 400 mg od is no less effective than a 14-day treatment with the comparator, levofloxacin 500 mg od plus metronidazole 500 mg bid, in adults with uncomplicated PID. Indeed, the lower limit of the 95% CI of the difference between the two clinical success rates (moxifloxacin minus comparator group) at the TOC visit was greater than 15%, see Table 2. Clinical Response Table 2 presents an overview of efficacy results (ie, success rates) for clinical response at TOC in the PP, ITT, and MBV populations. The success rate for clinical response at TOC in the PP population, the primary efficacy variable, was almost identical in the two treatment groups and the statistical hypothesis of inferiority of moxifloxacin to the comparator regimen could be rejected at the 2.5% level. Except for mainland China, sample sizes are too small to draw conclusion based on data from a single country. The results in mainland China were very much similar to those in subjects from all countries. The ITT clinical response results support the results from the per protocol analysis. Overall conclusions on the clinical response rates at the TOC visit in the microbiologically valid and ITT with causative organisms populations should be made with caution, since the number of subjects in this subgroup is small. The microbiologically valid population represents only 12.1% of the entire population. This subgroup is too small to allow for meaningful overall conclusions. Concerning the subgroup of subjects with microbiologically documented infection, the apparent difference in clinical cure rates between the two treatment groups is driven by an imbalance in subjects assessed as clinical improvements (scored as non-successes), ie, 9 in the moxifloxacin group versus 0 in the levofloxacin plus metronidazole group. The combined cure plus clinical improvement totals were 28/30 for moxifloxacin compared to 26/26 for levofloxacin plus metronidazole. Table 3 shows clinical resolution rates between the treatment groups in selected subject subgroups. No major differences between treatment groups in the clinical cure rates were observed. Results of the clinical efficacy analyses based on data for the ITT population generally were consistent with those in the PP population. Bacteriological Response The bacteriological success rates were high in both the moxifloxacin group (27/30=90%) and the comparator group (22/26=85%, 95% CI: -12.7% to 20.3%). The bacteriological success rates demonstrate that the apparent differences in clinical outcome between moxifloxacin and comparator in the microbiologically valid subjects are likely to be an artifact. Several factors may have contributed to the divergent clinical and bacteriological outcomes in this study. First, the small number of microbiologically evaluable subjects with pathogens at study entry (30 moxifloxacin subjects and 26 comparator subjects) limits the conclusions that can be drawn regarding bacteriological outcome. In addition, the difference between clinical and bacteriological success rates was driven mainly by high proportion of subjects with clinical improvement. In many cases, clinical improvement was associated with eradication, thus minimizing difference between the groups. Table 4 presents bacteriological successes at TOC by most frequently diagnosed organisms. In the MBV population, N. gonorrhoeae was diagnosed in 4 moxifloxacin subjects and 2 comparator subjects, and C. trachomatis was diagnosed in 8 moxifloxacin subjects and 12 comparator subjects. All 4 moxifloxacin subjects (100%) with N. gonorrhoeae and all 8 moxifloxacin subjects with C. trachomatis present at pre-therapy had an outcome of eradication at TOC. In the comparator group, 1 (50%) of the 2 subjects with N. gonorrhoeae and 10 of the 12 (83.3%) subjects with C. trachomatis present at pre-therapy had an outcome of eradication at TOC; the outcome in the other 3 subjects (1 [50%] with N. gonorrhoeae and 2 [16.7%] with C. trachomatis) was persistence. Overall, the number of individuals with diagnosed N. gonorrhoeae or C. trachomatis, was too low for meaningful comparisons or conclusions. Table 2: Overview of Efficacy Results (ie, Success Rates a ) for Clinical Response at TOC in the PP, microbiologically valid, ITT and ITT with causative organisms Populations Per Protocol Moxifloxacin Comparator 95% CI b n/n (%) n/n (%) Lower (%) Upper (%) Overall efficacy population 152/194 (78) 155/190 (82) Microbiologically valid China Mainland 110/138 (80) 102/128 (80) Indonesia 6/7 (86) 9/9 (100) Korea 8/11 (73) 7/11 (64) Philippines 10/13 (77) 13/15 (87) Pakistan 2/5 (40) 4/4 (100) Thailand 8/9 (89) 11/12 (92) China Taiwan 8/11 (73) 9/11 (82) Overall 19/30 (63) 26/26 (100) China Mainland 13/19 (68) 16/16 (100)
6 Table 2: Overview of Efficacy Results (ie, Success Rates a ) for Clinical Response at TOC in the PP, microbiologically valid, ITT and ITT with causative organisms Populations Valid for safety/intent to treat Moxifloxacin Comparator 95% CI b n/n (%) n/n (%) Lower (%) Upper (%) Indonesia 0/0 (0) 3/3 (100) Korea 0/1 (0) 0/0 (0) Philippines 3/6 (50) 5/5 (100) Thailand 2/3 (67) 2/2 (100) China Taiwan 1/1 (100) 0/0 (0) Overall 163/225 (72) 171/230 (74) China Mainland 113/151 (75) 111/155 (72) Indonesia 10/14 (71) 14/16 (88) Korea 8/12 (67) 8/13 (62) Philippines 10/15 (67) 13/15 (87) Pakistan 4/7 (57) 5/7 (71) Thailand 10/13 (77) 11/12 (92) China Taiwan 8/13 (62) 9/12 (75) Valid for safety/intent to treat with causative organisms Overall 23/36 (64) 30/34 (88) China Mainland 17/24 (71) 20/24 (83) Indonesia 0/1 (0) 3/3 (100) Korea 0/1 (0) 0/0 (0) Philippines 3/6 (50) 5/5 (100) Thailand 2/3 (67) 2/2 (100) China Taiwan 1/1 (100) 0/0 (0) a Success rate at TOC: No. of subjects with clinical response clinical cure / No. of subjects in population. b Hypothesis of inferiority of moxifloxacin rejected at the 2.5% level (ie, lower limit of CI > -15%) Source: Table /3.1, Table /3.2, Table /3.3, and Table /3.4 Table 3: Clinical Cure Rates at TOC in Selected Subject Subgroups (Per Protocol Population) Moxifloxacin Comparator (n = 194) (n=190) n/n a % n/n a % Overall resolution rate 152/194 (78%) 155/190 (82%) Age < 40 yrs 98/132 (74%) 111/135 (82%) > 40 yrs 54/62 (87%) 44/55 (80%) PID severity score /164 (78%) 125/155 (81%) /30 (80%) 30/35 (86%) Previous PID in the last 12 months None 102/133 (77%) 95/118 (81%) At least one episode 50/61 (82%) 60/72 (83%) Duration of symptoms Unknown 2/2 (100%) 3/3 (100%) before start of treatment 3 days 27/34 (79%) 36/40 (90%) > 3 days 123/158 (78%) 116/147 (79%) Condom use Sexual abstinence 38/48 (79%) 47/64 (73%) Only protected intercourse 113/140 (81%) 105/119 (88%) Unprotected intercourse 1/3 (33%) 3/6 (50%) Unknown 0/3 (0%) 0/1 (0%)
7 a No. of subjects with resolution in subgroup / total No. of subjects in subgroup Abbreviation: PID = pelvic inflammatory disease Source: Table /1.1.1, Table /1.2.1, Table /1.4.1, Table /1.5.1, and Table /1.7.1 Table 4: Bacteriological Success at TOC by Most Frequently Diagnosed Organisms (MBV Population) Overall Gram-positive aerobic Organism Moxifloxacin (n = 30) n/n a (%) Levofloxacin plus metronidazole (n = 26) n/n a (%) Staphylococcus aureus spp 3/3 (100) 3/4 (75) Gram-negative aerobic Neisseria gonorrhoeae 4/4 (100) 1/2 (50) Escherichia coli 6/7 (86) 2/2 (100) Proteus mirabilis 3/5 (60) 1/1 (100) Anaerobic organisms Peptostreptococcus spp 4/4 (100) 3/3 (100) Intracellular organisms Chlamydia trachomatis 8/8 (100) 10/12 (83) a No. of subjects with bacteriological success / No. of subjects with diagnosed organism Abbreviation: spp = species Source: Table /4.1 Results Summary Safety In the valid for safety population (moxifloxacin, 225 subjects; levofloxacin plus metronidazole, 230 subjects), treatment-emergent adverse events, and treatment-emergent drug-related adverse events were similar in the moxifloxacin and comparator groups (57% versus 57%, and 46% versus 49%, respectively). The 3 system organ classes in which the highest rates of adverse event occurred were gastrointestinal disorders (36% moxifloxacin versus 40% comparator); nervous system disorders (24% moxifloxacin versus 21% comparator); and general disorders and administration site conditions (8% moxifloxacin versus 6% comparator). The largest differences between treatment groups ( 2%) can be found in the SOC gastrointestinal disorders (36% moxifloxacin versus 40% comparator), nervous system disorders (24% moxifloxacin versus 21% comparator), general disorders and administration site conditions (8% moxifloxacin versus 6% comparator), psychiatric disorders (4% moxifloxacin versus 6% comparator), and cardiac disorders (1% moxifloxacin versus 3% comparator). The most commonly reported treatment-emergent adverse event in both the moxifloxacin (19% of subjects) and comparator (23% of subjects) treatment group was nausea. The only other adverse events reported in more than 5% of subjects in either treatment group were dizziness (reported in 17% and 16% of the moxifloxacin and comparator subjects), insomnia (reported in 3% and 6% of the moxifloxacin and comparator subjects), abdominal pain (reported in 4% and 6% of the moxifloxacin and comparator subjects) and vomiting (reported in 3% and 7% of the moxifloxacin and comparator subjects). No deaths were reported during the study. Four subjects experienced treatment-emergent serious adverse events, 3 moxifloxacin subjects and 1 comparator subject. Only one of the events, Stevens-Johnson syndrome, was considered drug related. This event occurred in a moxifloxacin-treated subject. Most adverse events reported in both treatment groups were mild or moderate in severity. Four subjects in the moxifloxacin group experienced adverse events of severe intensity, three in the comparator group. Of these, 3 events in each treatment group were considered drug related. Most adverse events resolved or had an improved outcome irrespective of whether they were assessed as drug related or not. Only 9 subjects in the moxifloxacin group reported an adverse event with outcome unchanged and none had an outcome of worsened. In the comparator group, 5 subjects experienced an adverse event that was unchanged and 2 had worsening as an outcome. The evaluation of significant changes of laboratory parameters did not reveal any relevant difference between treatments. No relevant treatment-related differences were detected in the analysis of vital signs. Conclusion(s) The results of the study provide evidence that moxifloxacin 400 mg PO od for 14 days is not clinically inferior in terms of clinical response rate to levofloxacin plus metronidazole for the treatment of uncomplicated PID. In addition, the safety profiles of moxifloxacin and of levofloxacin plus metronidazole regimens are similar.
8 Publication(s) Judlin P, Liao Q, Liu Z, Reimnitz P, Hampel B, Arvis P. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG Nov;117(12): doi: /j x. Epub 2010 Aug 18. Updated: 8 Nov 2012
9 Appendix to Clinical Study Synopsis Product Identification Information Product Type Drug US Brand/Trade Name(s) Avelox [Oral formulation] Brand/Trade Name(s) ex-us Generic Name Main Product Company Code Other Company Code(s) Chemical Description Other Product Aliases Avelox Avalox Actira Octegra Izilox Megaxin Proflox Promira Moxifloxacin BAY n/a 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro- 6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline- 3-carboxylic acid hydrochloride. n/a Date of last Update/Change: 11 September 2013
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationMANAGEMENT OF PELVIC INFLAMMATORY DISEASE
GYNAECOLOGY SERVICES NORTH CUMBRIA MANAGEMENT OF PELVIC INFLAMMATORY DISEASE Author/Contact DOCUMENT CONTROL Lufti Shamsuddin, ST4 Obs & Gynae Trainee / Nalini Munjuluri, Consultant Gynaecology Tel: 01228
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationUpdated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007
Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 1 Ongoing data from CDC 's Gonococcal Isolate Surveillance Project (GISP), including
More informationTubo-ovarian abscess in OPAT
Tubo-ovarian abscess in OPAT James Hatcher Consultant in Infectious Diseases and Medical Microbiology OUTLINE What is a tubo-ovarian abscess Current recommendations Our experience and challenges How to
More informationReduce the risk of recurrence Clear bacterial infections fast and thoroughly
Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological
More informationSynopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets
Synopsis Name of the sponsor Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Name of active ingredient Title of the study Study
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationSimplicef is Used to Treat Animals with Skin Infections
Simplicef is Used to Treat Animals with Skin Infections PRODUCT INFO Simplicef tablets are a semi-synthetic cephalosporin antibiotic cefpodoxime proxetil used to cure infections caused by the susceptible
More informationDoes flagyl treat gonorrhea and chlamydia
Does flagyl treat gonorrhea and chlamydia The Borg System is 100 % Does flagyl treat gonorrhea and chlamydia Mild Chlamydia infection, limited to the cervix, can be treated with a single dose of an antibiotic
More informationLefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results. September 18, 2017
Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results September 18, 2017 Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects
More informationUniversité catholique de Louvain, Louvain Drug Research Institute, Brussels, Belgium. Bayer Santé SAS, Loos, France
Communicating Comprehensive Safety Data Gained from Clinical Trials to the Scientific Community: Opportunities and Difficulties from an Example with Moxifloxacin P.M. Tulkens, 1 P. Arvis, 2 F. Kruesmann,
More informationCritical Appraisal Topic. Antibiotic Duration in Acute Otitis Media in Children. Carissa Schatz, BSN, RN, FNP-s. University of Mary
Running head: ANTIBIOTIC DURATION IN AOM 1 Critical Appraisal Topic Antibiotic Duration in Acute Otitis Media in Children Carissa Schatz, BSN, RN, FNP-s University of Mary 2 Evidence-Based Practice: Critical
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.04 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for important
More informationPharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J
Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation
More informationBacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups
Bacterial skin and soft tissues infections (SSTI) are one of the most common 1 infections among different age groups Gram-positive bacteria are the most frequently isolated pathogens from SSTI, with a
More informationRandomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis
Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis Steve SM Wong Alice Ho Miu Ling Nethersole Hospital Background PD peritonitis is a major cause of PD
More informationLyme disease: diagnosis and management
National Institute for Health and Care Excellence Final Lyme disease: diagnosis and management [D] Evidence review for the management of erythema migrans NICE guideline 95 Evidence review April 2018 Final
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More informationMoxifloxacin (as hydrochloride) 400 mg Tablets WHOPAR part 6 November 2017 (Hetero Labs Limited), TB 315
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationDuration of antibiotic therapy:
Duration of antibiotic therapy: How low can you go? Thomas Holland, MD Hilton Head, SC July 2017 Disclosures Consulting: The Medicines Company, Basilea Pharmaceutica Adjudication committee: Achaogen Grant
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationCLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:
CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nuzyra) Reference Number: CP.PMN.## Effective Date: 11.20.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Coding Implications Revision Log See Important Reminder
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 October 2013 EMEA/CVMP/EWP/141272/2011 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in cattle
More informationClinical Policy: Clindamycin (Cleocin) Reference Number: CP.HNMC.08 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Cleocin) Reference Number: CP.HNMC.08 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy
More informationSrirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai.
Indian Medical Gazette JUNE 2015 225 Comparative A Randomized, Open Label, Prospective, Comparative Evaluating the Efficacy and Safety of Fixed Dose Combination of Cefpodoxime 200 Mg + Clavulanic Acid
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Healthcare Associated
More informationApril 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID
VOLUME FOUR; ISSUE 4 April 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID InPHARMation Pharmacy and Therapeutics Committee Update April 25 th, 2018 Meeting The Pharmacy and Therapeutics Committee
More informationCephalosporins, Quinolones and Co-amoxiclav Prescribing Audit
Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit Executive Summary Background Antibiotic resistance poses a significant threat to public health, as antibiotics underpin routine medical practice.
More informationTHE VETERINARIAN'S CHOICE. Compendium clinical Trials. Introducing new MILPRO. from Virbac. Go pro. Go MILPRO..
THE VETERINARIAN'S CHOICE. Introducing new MILPRO from Virbac. Compendium clinical Trials Go pro. Go MILPRO.. milbemycin/praziquantel Content INTRODUCTION 05 I. EFFICACY STUDIES IN CATS 06 I.I. Efficacy
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationTreating Rosacea in the Era of Bacterial Resistance. This presentation is sponsored by Galderma Laboratories, L.P.
Treating Rosacea in the Era of Bacterial Resistance This presentation is sponsored by Galderma Laboratories, L.P. Lecture Discuss rosacea as an inflammatory condition Assess the psychosocial impact of
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationStudy population The target population for the model were hospitalised patients with cellulitis.
Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals Vinken A G, Li J Z, Balan D A, Rittenhouse B E, Willke R J, Goodman C Record Status This is a
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Doxycycline Hyclate (Acticlate, Doryx), Doxycline (Oracea), Minocycline (Solodyn, Ximino) Reference Number: CP.CPA.120 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business:
More informationInfection Comments First Line Agents Penicillin Allergy History of multiresistant. line treatment: persist for >7 days they may be
Gastrointestinal Infections Infection Comments First Line Agents Penicillin Allergy History of multiresistant Campylobacter Antibiotics not recommended. Erythromycin 250mg PO 6 Alternative to first N/A
More informationCommunity Acquired Pneumonia: An Update on Guidelines
Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.24 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for important
More informationNovember 2017 Review Nov Signatures of those developing the Patient Group Direction Job Title Name Signature Date Doctor Stephanie Dundas
Supply of Trimethoprim 200mg tablets by Community Pharmacists for the Management of Uncomplicated Urinary Tract Infections in Female Patients from 16 and 65 years of age. November 2017 Review Nov 2019
More informationDrug Class Literature Scan: Otic Antibiotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationPublic Assessment Report Paediatric data. EXOCIN (OCUFLOX) Ofloxacin. Marketing Autorisation Holder: Allergan
Public Assessment Report Paediatric data EXOCIN (OCUFLOX) Ofloxacin Marketing Autorisation Holder: Allergan Rapporteur: Co-Rapporteur: Currently approved indication(s): Pharmaceutical form(s) and strengths
More informationDevelopment of Drugs for HAP-VAP. Robert Fromtling, MD
Development of Drugs for HAP-VAP Robert Fromtling, MD Hospital-Acquired & Ventilator- Associated Pneumonia (HAP-VAP) The EMA 2015 roadmap recognizes the need for new antibiotics New drugs for HAP-VAP are
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationIntra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018
Intra-Abdominal Infections Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Select guidelines Mazuski JE, et al. The Surgical Infection
More informationUnasyn alternative if penicillin allergic
Unasyn alternative if penicillin allergic The following guidelines have been developed to assist physicians with the appropriate selection of prophylactic and empiric antibiotic therapy for potential and.
More informationSECTION 3A. Section 3A Criteria for Optional Special Authorization of Select Drug Products
SECTION 3A Criteria for Optional Special Authorization of Select Drug Products Section 3A Criteria for Optional Special Authorization of Select Drug Products CRITERIA FOR OPTIONAL SPECIAL AUTHORIZATION
More informationAZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES
AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES Update in Medicine and Primary Care Whitney R. Buckel, PharmD, BCPS-AQ ID System Antimicrobial Stewardship Pharmacist Manager OBJECTIVES 1. List three antibiotics
More informationUTI Dr S Mathijs Department of Pharmacology
UTI Dr S Mathijs Department of Pharmacology Introduction Responsible for > 7 million consultations annually 15% of all antibiotic prescriptions 40% of all hospital acquired infections Significant burden
More information17 th Club Phase 1 Annual Meeting April 5, Pierre Maison-Blanche Hopital Bichat, Paris, France
Practical Issues for the clinical evaluation of QT/QTc interval prolongation 17 th Club Phase 1 Annual Meeting April 5, 2018 Pierre Maison-Blanche Hopital Bichat, Paris, France Disclosure Chiesi Pharmaceuticals
More informationShort Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil
Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil D. Adam, MD PhD, Munich, Germany H. Scholz, MD PhD, Berlin,
More informationAuthor - Dr. Josie Traub-Dargatz
Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary
More informationWHO Guideline for Management of Possible Serious Bacterial Infection (PSBI) in neonates and young infants where referral is not feasible
WHO Guideline for Management of Possible Serious Bacterial Infection (PSBI) in neonates and young infants where referral is not feasible Department of Maternal, Newborn, Child & Adolescent Health Newborn
More informationPhase III Clinical Trial of Moxifloxacin Hydrochloride in the Treatment of Acute Exacerbations of Chronic Bronchitis in Comparison with Azithromycin
ORIGINAL ARTICLE JIACM 2002; 3(4): 360-6 Phase III Clinical Trial of Moxifloxacin Hydrochloride in the Treatment of Acute Exacerbations of Chronic Bronchitis in Comparison with Azithromycin SH Talib*,
More informationStudy Protocol. Funding: German Center for Infection Research (TTU-HAARBI, Research Clinical Unit)
Effectiveness of antibiotic stewardship interventions in reducing the rate of colonization and infections due to antibiotic resistant bacteria and Clostridium difficile in hospital patients a systematic
More informationSubmission for Reclassification
Submission for Reclassification Fucithalmic (Fusidic Acid 1% Eye Drops) From Prescription Medicine to Restricted Medicine (Pharmacist Only Medicine) CSL Biotherapies (NZ) Limited 666 Great South Road Penrose
More informationMastitis in ewes: towards development of a prevention and treatment plan
SCHOOL OF LIFE SCIENCES, UNIVERSITY OF WARWICK Mastitis in ewes: towards development of a prevention and treatment plan Final Report Selene Huntley and Laura Green 1 Background to Project Mastitis is inflammation
More informationamoxycillin/clavulanate vs placebo in the prevention of infection after animal
Archives of Emergency Medicine, 1989, 6, 251-256 A comparative double blind study of amoxycillin/clavulanate vs placebo in the prevention of infection after animal bites P. H. BRAKENBURY & C. MUWANGA Accident
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More informationStudy of First Line Antibiotics in Lower Respiratory Tract Infections in Children
IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-issn:2278-3008, p-issn:239-7676. Volume 2, Issue 4 Ver. VI (Jul Aug 207), PP 47-55 www.iosrjournals.org Study of First Line Antibiotics in
More informationInterventions for children with ear discharge occurring at least two weeks following grommet(ventilation tube) insertion(review)
Cochrane Database of Systematic Reviews Interventions for children with ear discharge occurring at least two weeks following grommet(ventilation tube) insertion(review) Venekamp RP, Javed F, van Dongen
More informationClinical Practice Standard
Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:
More informationFederal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
BAYER HEALTHCARE LLC Animal Health Division USA Product Label http://www.vetdepot.com P.O. BOX 390, SHAWNEE MISSION, KS, 66201 0390 Customer Service Tel.: 800 633 3796 Customer Service Fax: 800 344 4219
More informationDelayed Prescribing for Minor Infections Resource Pack for Prescribers
Delayed Prescribing for Minor Infections Resource Pack for Prescribers Background: Antibiotic resistance is an alarming threat to modern healthcare, and infectious illness remains a major global threat
More informationJob Title Name Signature Date
Supply of Trimethoprim 200mg tablets By Community Pharmacists for the Management of Uncomplicated Urinary Tract Infections in Female Patients Protocol number 473 Version 1 Date protocol prepared: November
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET FOR: Cadorex 300 mg/ml solution for injection for cattle, sheep and pigs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More informationWomen s Antimicrobial Guidelines Summary
Women s Antimicrobial Guidelines Summary 1. Introduction and Who Guideline applies to This guideline has been developed to deliver safe and appropriate empirical use of antibiotics for patients at University
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Antibiotic treatment and monitoring for suspected or confirmed early-onset neonatal infection bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to
More informationCase 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance
Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance 22nd Congress of the EAHP "Hospital pharmacists catalysts for change", 22-24 March 2017, Cannes Disclosure
More informationchoice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*
Virbac Dermatology Palatable Tablets The choice First generation cephalosporin for skin infections Now registered for ONCE daily administration* are only available under Veterinary Authorisation. www.virbac.co.nz
More informationNewsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017
Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationUSA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only
USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer
More informationTHERAPY OF ANAEROBIC INFECTIONS LUNG ABSCESS BRAIN ABSCESS
THERAPY OF ANAEROBIC INFECTIONS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu LUNG ABSCESS A lung abscess is a localized pus cavity in
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 250 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PT, RO,
More informationUnshakeable confidence
NEW PRODUCT OF THE YEAR as voted by vets for the 2nd year running** Unshakeable confidence Osurnia is the only otitis externa* treatment that applies like a liquid and stays like a gel. Right where you
More informationDOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTIPRIO safely and effectively. See full prescribing information for OTIPRIO. OTIPRIO (ciprofloxacin
More informationScientific Discussion post-authorisation update for Rheumocam extension X/007
5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution
More informationPrescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children
Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,
More informationUPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM
UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health
More informationISMP Canada HYDROmorphone Knowledge Assessment Survey
ISMP Canada HYDROmorphone Knowledge Assessment Survey Knowledge Assessment Questions 1. In an equipotent dose, HYDROmorphone is more potent than morphine. True False Unsure 2. HYDROmorphone can be given
More informationLINEE GUIDA: VALORI E LIMITI
Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Ophtocycline 10 mg/g eye ointment for dogs, cats and horses (AT, BE, BG, CY, CZ, EL, ES, HR, HU, IE, IT, LU, NL,
More informationCipro for klebsiella uti
Cipro for klebsiella uti Search Can UTI be an effective treatment for Klebsiella Pneumoniae? It is safe or dangerous to use UTI while suffering from Klebsiella Pneumoniae? 87 discussions on Treato. instock
More information